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Reexpression of the fetally expressed -myosin heavy chain (-
MHC) gene is a well documented marker of pathological cardiac
hypertrophy and normal aging in many experimental models. To
gain insights into factors affecting this reexpression of -MHC
within the complex anatomical structure of the heart, we investi-
gated the spatial pattern of its expression at the level of single cells
during aging and hypertrophy. We generated mice that express
yellow fluorescent protein fused to the N terminus of the -MHC
and examined its expression pattern during normal aging and in
mice with hypertrophy induced by constitutive expression of a
renin transgene. The localization of fibrosis within the hearts also
was determined by using a fluorescent lectin. The results show that
reexpression of -MHC occurs in discrete subsets of myocytes
within the subendocardium rather than uniformly throughout the
heart, that -MHC induction is not an obligatory consequence of
cellular hypertrophy, and that -MHC-expressing cells in the nor-
mal aging heart and the hypertrophic heart are distributed pre-
dominantly in clusters within and surrounding foci of fibrosis. We
conclude that -MHC gene expression in the normal aging adult
and hypertrophic mouse heart is a marker of fibrosis rather than of
cellular hypertrophy.
genetic reprogramming
The adult myocardium responds to extrinsic forms of stress,such as hypertension, myocardial infarction, and pressure
overload, by a hypertrophic growth response (reviewed in ref.
1). Left ventricular hypertrophy caused by chronic hyperten-
sion is accompanied by two key pathological processes: myo-
cyte hypertrophy and fibrosis. Hypertrophic growth of myo-
cytes is initiated by physical stress and by endocrine, paracrine,
and autocrine factors that activate a variety of receptors
(reviewed in refs. 2–4). These receptors trigger multiple
cytoplasmic signal transduction cascades that regulate gene
expression (5), resulting in increased cell size due to increased
synthesis of sarcomeric and other proteins together with
reorganization of myofibrillar structures
Fibrosis is a complex multifactorial process involving recip-
rocal interactions between stimulatory and inhibitory factors
that lead to increased collagen deposition (6–8). Myocardial
fibrosis caused by hypertension is associated with increased
accumulation of type I and III collagens within the adventitia of
coronary arteries (perivascular fibrosis), which progressively
extends into the neighboring interstitial spaces (interstitial fi-
brosis). Myocardial fibrosis also results from ischemia due to
insufficient coronary reserve, involves the actions of plasma and
local peptides, and usually accompanies nonphysiological left
ventricular hypertrophy; in addition, its consequences include
loss of functionality of the myocardium due to abnormal diastolic
stiffness. When severe, myocardial fibrosis contributes to fatal
cardiac arrhythmias due to interruptions in the normal propa-
gation of electrical impulses (9).
A molecular feature common to cardiac hypertrophy and
heart failure is the induction of a fetal gene program (reviewed
in refs. 10 and 11). In the mouse and rat, cardiac -myosin heavy
chain (-MHC) is a fetal-specific isoform whose expression in
ventricular myocytes is down-regulated to low levels soon after
birth. However, in normal animals, -MHC expression gradually
increases in an age-dependent manner (12). Increased expres-
sion of the -MHC gene also is observed in most experimental
models of cardiac hypertrophy and heart failure. -MHC ex-
pression increases may directly affect cardiac function, as judged
by a reduction in myofibrillar ATPase activity and reduced
shortening velocity of cardiac myofibers in animals that express
-MHC in place of -MHC (13). The up-regulation of -MHC
can be reversible in conditions, such as the regression of hyper-
trophy (14, 15), the rescue of murine models of heart failure (16),
and in humans who respond favorably to beta blocker treatments
(17–19). Recent studies suggest that reexpression of -MHC may
contribute to the overall poor functioning of the hypertrophic
ventricle (13, 20).
Surprisingly little is known, however, about the manner in
which individual myocytes respond during the perinatal decrease
and subsequent increase in -MHC expression accompanying
normal aging or hypertrophy. Thus, it is not clear whether this
up-regulation is mediated by an increase in expression levels in
all myocytes or by an increase in expression levels in only discrete
subsets. Also lacking is an understanding of the precise rela-
tionship between the presence or absence of hypertrophy of
individual cells and the state of their -MHC expression. Thus,
it is not known whether reexpression of -MHC is an indicator
of increased cell size that leads to cardiac hypertrophy or a
different event that accompanies cardiac hypertrophy. Accord-
ingly, we investigated the precise distribution of -MHC expres-
sion at the level of single cells within the three-dimensional space
of the normal perinatal heart, in the normal adult heart, and in
the hypertrophic heart. The resulting data show that reexpres-
sion of -MHC occurs in only a subset of myocytes, is not
obligatorily linked to cellular hypertrophy, and occurs predom-
inantly in myocytes associated with regions of fibrosis.
Results
Generation of Yellow Fluorescent Protein (YFP)–-MHC Animals. To
identify individual -MHC expressing cells, we used gene tar-
geting to mark the native -MHC gene by appending the coding
sequence of YFP to the 5 end of the coding sequence of -MHC,
thereby generating a YFP–-MHC fusion protein with YFP
joined to the N terminus of -MHC (Fig. 1). Previous work has
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indicated that a comparable N-terminal fusion between GFP and
MHC results in a functional protein with WT enzymatic activity
in vitro and can replace the normal MHC gene in Dictostylium in
vivo (21). To minimize potential differences between native 
-MHC and YFP–-MHC genes, we ensured that the Kozak
sequence and the intronexon boundaries of the -MHC gene
remained unchanged. We also used a valine–proline sequence
between YFP and -MHC by following published accounts that
this type of MHC fusion gene is appropriately folded in vivo (22).
The selection cassette (23) consists of two linked genes as
shown in Fig. 1: CRE (driven by the testis-specific promoter
tACE), and Neo, both flanked by loxP sites. With this selection
cassette, transmission of a targeted allele through the male
germline activates CRE expression, causing deletion of the
entire selection cassette and leaving only a single 34-bp loxP site
at the insertion site (23). We inserted the selection cassette
within intron 1 of the targeting construct to minimize any
potential deleterious effects of this remaining loxP site. All
factors controlling expression of the normal -MHC gene are
expected to be preserved because the fusion gene is at the
normal chromosomal position of the -MHC and differs only by
the presence of the loxP sequence. Heterozygous transgenic
animals carrying one copy of the fusion gene and one copy of the
WT -MHC gene (Yb, referred to below as Yb) were used for
our studies. These animals were born at the expected Mendelian
ratios and show no detected abnormalities.
Developmental Expression of YFP–-MHC. To determine the expres-
sion pattern of the Yb allele perinatally, ventricular sections
from neonatal-day-1 hearts were examined by using confocal
microscopy. Fig. 2A shows the YFP fluorescence of a transverse
heart section from a Yb, neonatal-day-1 pup. As illustrated, the
1-day-old Yb heart shows high expression of YFP throughout the
tissue. In higher-magnification images, the presence of fluores-
cent A bands within sarcomeres (Fig. 2B) clearly show that the
YFP–-MHC polypeptide retains all features necessary for
incorporation into sarcomeres.
To determine the postnatal changes in the distribution of cells
expressing YFP–-MHC and the levels of its expression, we
examined ventricular sections of Yb animals from neonatal day
8 by using YFP fluorescence. Fig. 2C shows that expression of the
fusion protein is reduced to low levels by day 8 and that, at this
age, most myocytes show either low or undetectable levels of
YFP–-MHC. However, despite the overall low level of YFP–
-MHC expression, high-resolution confocal images show a few
sparsely scattered cells that retain a high level of expression (Fig.
2D). These perinatal changes in YFP–-MHC expression are in
agreement with the known expression pattern of WT -MHC in
the mouse (24).
To investigate the cellular pattern of -MHC reexpression that
occurs during normal aging, we examined the expression of the
Yb fusion protein at 5 weeks and 9 months of age. By 5 weeks,
expression of YFP–-MHC is essentially off, with almost all
ventricular myocytes having levels of yellow fluorescence indis-
tinguishable from the low levels of autofluorescence observed in
WT animals, although a few cells with fluorescence are occa-
sionally detected in some Yb animals (data not shown). By 9
months, the vast majority of cells still show undetectable levels
of YFP fluorescence, but there were some clearly fluorescent
cells distributed in small clusters (Fig. 2 E and F). Thus, in a
normal animal the age-related increase in -MHC expression is
mediated by a large increase in -MHC expression levels in
clusters of a few cells, rather than by a uniform small increase in
expression of most cells.
YFP–-MHC Expression During Hypertrophy Occurs in Discrete Subsets
of Myocytes. To determine the pattern of -MHC reexpression
during hypertrophy, we mated Yb mice to mice carrying a single
copy of a renin transgene (RenTg) inserted at the ApoAI CIII
locus. This transgene directs the chronic constitutive secretion of
renin from the liver (25, 26), leading to high plasma renin levels
(6-fold of those in WT mice) and to cardiac hypertrophy.
RenTg animals have chronic hypertension and develop concen-
tric cardiac hypertrophy, and more than half die before 9 months
of age (25, 26). For our experiments, we used 7- to 9-month-old
male and female mice of a mixed 129B6 genetic background
that have one copy of the YFP–-MHC gene and one copy of



















Fig. 1. Generation of the -MHC fusion allele. (Top) WT -MHC gene (upper
line) and targeting construct (lower line). (Middle) Targeted allele in ES cells.
(Bottom) YFP–-MHC fusion allele after germline transmission. Open boxes
represent 5 UTRs, and solid boxes represent translated exons. The coding
sequence of YFP is shown as a shaded box within exon 4, and loxP sites are
shown as triangles. A selection cassette (23) containing a testis promoter-
driving CRE (tACE-CRE) and a Neo gene is inserted into intron 1; the selection
cassette is not drawn to scale.
Fig. 2. Developmental regulation of the YFP–-MHC fusion protein. Con-
focal yellow fluorescent images of ventricular sections from a 1-day-old
neonate (A and B), 8-day-old pup (C and D), and 9-month-old adult (E and F)
imaged with a 20 objective (A, C, and E), a 60 objective (D and F), or a 60
objective with 3.5 optical zoom (B; final magnification, 210). Identical
settings were used to procure images for the series of 20 or 60 objectives.
(Scale bars: 20 m.)











The YbRenTg animals, as expected, show significant in-
creases in the heart weightbody weight ratio relative to the
littermate Yb animals without the RenTg as well as increases in
mRNA levels for atrial natriuretic peptide (ANP) and -MHC
(Fig. 3 A–C). These increases are virtually identical in magnitude
to those observed for RenTg alone (25, 26). To test whether
expression of YFP–-MHC allele parallels expression of the WT
-MHC allele, we used quantitative RT-PCR to determine the
levels of YFP and WT -MHC mRNAs in the ventricles of 7- to
9-month-old animals. Fig. 3D illustrates the resulting data as a
scatterplot matrix of the expression levels of Yb and -MHC
from individual animals and demonstrates that expression of
YFP is highly correlated (r  0.82, P  0.002), with expression
of the WT -MHC allele over a 20-fold range. Thus, the
YFP–-MHC fusion allele faithfully tracks the expression of
-MHC. We also determined whether expression of the YFP–
-MHC allele parallels expression of ANP, a well conserved
marker of cardiac hypertrophy. As shown in Fig. 3E, YFP
expression also is highly correlated with that of ANP (r  0.92,
P  0.0001).
To assess the cellular distribution pattern of YFP–-MHC
re-expression in the YbRenTg animals, ventricular sections
were analyzed by confocal microscopy. Fig. 4 A and B compare
the expression patterns of the fusion protein within a typical Yb
control (heart weightbody weight ratio  5.6 mgg; Fig. 4A) and
YbRenTg heart (heart weightbody weight ratio  7.8 mgg;
Fig. 4B) at 7 to 9 months of age. In the animal made hypertrophic
with the RenTg, a marked increase in YFP–-MHC expression
is readily observed, with many but not all cells expressing high
levels of the YFP–-MHC protein. Nevertheless, although some
cells show high levels of expression of the fusion protein, many
other cells show undetectable levels of expression. The YFP–-
MHC-expressing cells are predominantly within the left ventric-
ular subendocardium, with the subepicardium and right ventricle
showing few YFP–-MHC-expressing cells. Analyses of ventric-
ular sections from YbRenTg animals cut in the coronal plane
(Fig. 4C) show that the cells expressing YFP–-MHC within the
subendocardium extend from the base to the apex of the left and
right ventricle. Thus, reexpression of YFP–-MHC occurs in
discrete subsets of myocytes rather than uniformly in all. These
cells are more frequent in the subendocardium, which is con-
sistent with previous observations (27).
Reexpression of YFP–-MHC Is Associated with Fibrosis. To gain
further insights into the nature of the distribution of YFP–-
MHC-expressing cells within the hearts of YbRenTg animals,
we examined whether the clustered expression pattern of YFP–
-MHC is correlated with the focal myocardial fibrosis that is
known to occur in the RenTg animals (25). Masson’s trichrome
staining of paraffin sections is a conventional stain for fibrosis,
but sections prepared in this manner lose their YFP fluores-
cence. We therefore used fluorescent wheat germ agglutinin
(WGA), a lectin that binds to sugar residues and has previously
shown to demonstrate the presence of the highly glycosylated
protein collagen in tissue sections (28, 29). We confirmed that
WGA binds to collagen by showing that it binds to the same
interstitial structures that stain blue with Masson’s trichrome in
serial sections of a hypertrophic heart (Fig. 10, which is published
as supporting information on the PNAS web site). Increases in
WGA lectin binding consequently provide a surrogate for in-
creased fibrosis. Fig. 4D shows the WGA fluorescence (pseudo-
colored blue) of the same section whose Yb fluorescence
(yellow) was shown in Fig. 4C. Comparison of these two images
clearly demonstrates that the distribution of increased WGA
staining coincides remarkably well with the distribution of the
cells reexpressing YFP–-MHC. Thus, YFP–-MHC-expressing
cells surround or are included within areas of increased WGA
stain. Indeed the areas of fibrosis can be predicted from the
clustering of yellow cells or vice versa. Fig. 5 A–C illustrates
high-magnification confocal images that show markedly in-
creased interstitial fibrosis surrounding myocytes expressing
YFP–-MHC (Fig. 5 A–C, areas encircled by solid ovals) but not
around neighboring areas that do not express YFP–-MHC (Fig.
5 A–C, areas encircled by dashed ovals). Similar correlation is
also seen in Yb homozygous animals (animals harboring two
copies of the YFP–-MHC fusion allele) made hypertrophic by
aortic banding (data not shown). We next quantified the asso-
ciation between YFP–-MHC expression and fibrosis. Confocal
images of left ventricle from a 6-month-old YbRenTg animal
were digitally dissected into fibrotic and nonfibrotic areas, and
fibrosis (mean WGA pixel intensity) and the YFP expression
























































































Fig. 3. Induction of hypertrophy. (A–C) Comparisons of heart weightbody
weight ratios (HwBw) (A) and mRNA expressions relative to mean of control
(Relative Exp) for -MHC (b MHC; B) and ANP (C) of 7- to 9-month-old control
animals (Yb) and YbRenTg animals. (D and E) Bivariate analyses between
mRNA levels as the log10 of the relative expression of YFP [Log (Rel YFP)] and
log10 of the relative expression of WT -MHC [Log (Rel wt bMHC)] (D) or ANP
[Log (Rel ANP)] (E). Circles denote control animals (Yb); triangles denote
YbRenTg animals.
Fig. 4. Distribution of YFP–-MHC-expressing cells. Yellow fluorescence
confocal images of ventricular sections from Yb control mice (A, transverse)
and YbRentg mice (B, transverse; and C, coronal). (D) A fluorescent image
(pseudocolored blue) of the same section as for C that visualizes a lectin stain.
Overlapping images were acquired with a 4 objective and were stitched
together by using ImageJ. The separation of individual images is illustrated in
Fig. 9, which is published as supporting information on the PNAS web site.
High levels of staining of WGA around the edges of the tissue in D are due to
lectin binding to the pericardium.
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illustrates the resulting data in the form of a scatterplot matrix
and demonstrates a high and significant correlation between
WGA staining and YFP expression (r  0.77, P  0.0001). Thus,
fibrosis and YFP expression are closely associated within the
hypertrophic heart.
One of the hallmark of hypertensive myocardial fibrosis is
perivascular fibrosis, which is obvious in RenTg mice, as previ-
ously described (25). We therefore asked whether -MHC
reexpression is associated with perivascular fibrosis as well as
with interstitial fibrosis. Fig. 6A shows that clusters of YFP–-
MHC cells also are found surrounding coronary vessels, dem-
onstrating that YFP–-MHC reexpressing myocytes are associ-
ated with perivascular and interstitial fibrosis. RenTg animals
display a well documented age-dependent increase in the levels
of myocardial fibrosis (30). To determine whether this increase
in fibrosis is associated with an increase in the number of
YFP–-MHC cells, we compared ventricular sections from
5-month-old YbRenTg animals that show low levels of fibrosis
with those from 15-month-old YbRenTg animals that show
markedly higher levels of fibrosis. Fig. 11, which is published as
supporting information on the PNAS web site, shows the results
of this comparison and demonstrates that the increased area of
fibrosis is associated with a clear increase in the number of
YFP–-MHC-expressing cells (Fig. 11 A and C). Thus, the
age-dependent increases in fibrosis in RenTg animals are closely
paralleled by increases in the number of YFP–-MHC-
expressing cells.
Diffuse Scattering of YFP–-MHC-Expressing Cells. We also find, in
addition to the YFP–-MHC cells associated with areas of
fibrosis, a few YFP–-MHC-expressing cells (10% of the
expressing cells) that are distributed singly and not associated
with any increase in WGA staining. These cells are present in low
numbers in control Yb animals and in higher numbers in
YbRenTg animals. These singletons contact cells that do not
express YFP–-MHC and are otherwise indistinguishable from
these nonexpressing cells (Fig. 6B). Note that the nonexpressing
cells adjacent to the expressing cells show no yellow fluores-
cence, not just a reduced level. Indeed, the fluorescence of these
cells is indistinguishable from background fluorescence in ani-
mals that have no YFP–-MHC gene.
Cellular Hypertrophy Can Occur Without YFP–-MHC Expression. We
tested whether the reexpression of YFP–-MHC in only some of
the cells was due to a greater degree of hypertrophy of the
YFP–-MHC-expressing cells compared with nonexpressing
cells in the same region of the heart. Heart sections were stained
with fluorescent WGA, and morphometrical analyses of the
cross-sectional areas of cells within the left ventricular free wall
from Yb control and YbRenTg animals were conducted. Fig.
7A shows that YbRenTg animals, as expected from their overall
hypertrophic state, show a highly significant increase in the
average cross-sectional areas of cardiac myocytes in the suben-
docardium compared with control animals. We then asked
whether in YbRentg animals the YFP–-MHC-expressing cells
were larger than the nonexpressing cells in the same regions by
simultaneously assessing their cross-sectional areas and scoring
them for their YFP fluorescence. Fig. 7B shows the resulting
data, which clearly demonstrate that the average cross-sectional
areas of YFP–-MHC-expressing cells are not significantly
different from the cross-sectional areas of non-YFP–-MHC-
expressing cells in the same region of the heart. Thus, YFP–-
MHC-expressing cells are no more hypertrophic than non-YFP–
-MHC-expressing cells. Taken together, these data
demonstrate that the YFP–-MHC-expressing cells in RenTg
animals are a subset of hypertrophic cells and that the increase
in cell size accompanying hypertrophy is associated with but not
sufficient to induce reexpression of YFP–-MHC.
Reexpression of YFP–-MHC During Normal Aging Is Associated with
Fibrosis. We noted above (Fig. 2E) that normal control animals
show an increase in the number of YFP–-MHC-expressing cells
as they age. We therefore asked whether the YFP–-MHC-
reexpressing cells in these nonhypertrophic but aging hearts were


























Fig. 5. Association of -MHC expression with fibrosis. (A–C) Confocal images
of transverse sections from a YbRenTg heart imaged with a 20 objective.
Yellow fluorescent images for YFP (A) and TRITC (B) for WGA lectin (pseudo-
colored blue) were acquired from the same section and merged (C) with
ImageJ. (Scale bar: 100 m.) (D) Bivariate analysis between YFP expression and
fibrosis as log10 of mean YFP pixel intensity [Log (Av. YFP intensity)] and log10
of mean WGA pixel intensity [Log (Av. WGA intensity)].
Fig. 6. YFP–-MHC expression in individual cells. Shown are merged images
for YFP and fluorescent WGA lectin (pseudocolored blue) of ventricular
sections from hypertrophic YbRenTg hearts with a 20 objective. The image


































Fig. 7. Morphometeric analyses. (A) Cross-sectional areas of myocytes from
Yb control (open bar) and YbRenTg hearts (black bars) irrespective of their
fluorescence. (B) Cross-sectional areas of the same myocytes from YbRenTg
animals used in A but grouped according to their yellow fluorescence (Yellow
cells or Non-Yellow cells). A total of 300 cells were analyzed for each genotype.











mice (31). We compared ventricular sections from 9- and
26-month-old Yb animals. Fig. 8 shows the result of this com-
parison, which demonstrates that increases in fibrosis [from 1.6%
of tissue in the 9-month-old animal (Fig. 8B) to 7.2% of total
tissue in the 26-month-old animal (Fig. 8D)] are associated with
increases in YFP–-MHC expression [from 2.7% of tissue in the
9-month-old animal (Fig. 8A) to 18.8% of tissue in the 26-month-
old animal (Fig. 8C)] and that the YFP–-MHC-expressing cells
cluster around these fibrotic areas (Fig. 8, white arrows) as well
as coronary vessels (Fig. 12, which is published as supporting
information on the PNAS web site). Furthermore, the sizes of
these cells are not significantly different from cells in the same
region that do not express YFP–-MHC (data not shown).
Discussion
We have described here the generation of a genetic model having
a YFP–-MHC fusion gene that allows a precise and accurate
assessment of the cellular distribution of -MHC expression in
adult mouse hearts. We have shown that the fusion gene follows
the expected regulation during perinatal development and ac-
curately tracks the expression of WT -MHC expression during
hypertrophy.
Our investigations demonstrate that increases in -MHC
expression that occur during cardiac hypertrophy as well as
during normal aging are mediated by increases in expression
levels in subsets of myocytes, rather than by increases in the
expression of -MHC in all myocytes. The YFP–-MHC-
expressing cells show markedly stronger yellow fluorescence
compared with nonexpressing cells in the same animals, which
show a level of f luorescence indistinguishable from cells of
animals that do not have the Yb fusion gene.
Our investigations show that reexpression occurs predomi-
nantly in hypertrophic cells clustered close to or within areas of
focal and interstitial fibrosis rather than in all hypertrophic cells.
Areas within the heart that are free from fibrosis include only a
small number of -MHC-expressing cells that are isolated rather
than clustered (see below). Thus, we find that many hypertrophic
myocytes in YbRenTg animals have undetectable levels of
YFP–-MHC expression, but the hypertrophic myocytes ex-
pressing YFP–-MHC always are associated with areas of fibro-
sis. The predominant subendocardial pattern of YFP–-MHC
reexpression also reflects this association, because myocardial
fibrosis is known to occur more frequently in this region (32).
The perivascular fibrosis found in hypertensive hypertrophy also
is faithfully mirrored by the reexpression of YFP–-MHC in
myocytes around coronary vessels, which is likewise consistent
with previous work showing -MHC reexpression around cor-
onary arteries in hypertrophic hearts (27). Of considerable
interest is our finding that the age-dependent reexpression of
YFP–-MHC in myocytes in normal control animals also is
associated with fibrosis (perivascular as well as interstitial fibro-
sis). Thus, we find that, in the absence of fibrosis, -MHC
reexpression in myocytes does not occur in normally sized or
hypertrophic myocytes. Experimental models of hypertrophy in
which substantial fibrosis does not occur, for example, hyper-
trophy due to either volume overload or subpressor doses of ang
II, are not associated with changes in -MHC reexpression
(33–35). In addition, recent studies with mice heterozygous for
the disruption of the gene for the major myocyte sodium channel
SCN5A show that mice reexpress -MHC and develop fibrosis
without the induction of cardiac hypertrophy (36). Together,
these associations suggest that -MHC reexpression does not
develop without fibrosis. A similar statement can be made with
respect to ventricular reexpression of ANP; increased ANP levels
do not invariably correlate with cardiac hypertrophy but are
observed always in the presence of cardiac pathology and
accompanied by fibrosis (interstitial and parivascular) (37–39).
It is not clear whether the association of -MHC-expressing
myocytes with areas of fibrosis is because of a cause-and-effect
relationship in either direction or because both are different
consequences of a common precursor event. However, it is
unlikely that simply the reexpression of -MHC in myocytes is
sufficient to induce fibrosis, given that chronic expression of the
-MHC transgene in adult hearts does not lead to fibrosis (13).
Furthermore, mechanical stretch of cultured rat neonatal ven-
tricular myocytes is sufficient to induce the expression of -MHC
without the need for or the development of fibrosis (11). Schultz
et al. (40) found that after aortic coarctation there was increased
-MHC in fgf2-null mice compared with WT mice but signifi-
cantly less fibrosis or hypertrophy, suggesting that neither hy-
pertrophy nor fibrosis causes -MHC expression. It is possible
that the same signal induces hypertrophy, fibrosis, and -MHC
expression but that -MHC induction does not require FGF2.
Some comment is required on our finding a few -MHC-
expressing cells scattered throughout the heart but not associ-
ated with notable increases in collagen deposition. These cells
are frequently singletons and are present in low numbers in
normal Yb control animals and in higher numbers in YbRenTg
animals, possibly because RenTg animals are already hypertro-
phic at birth (30). Because these cells are usually surrounded by
cells that do not express -MHC and are indistinguishable from
them except for their expression of YFP–-MHC, they are
unlikely to be a consequence of differential mechanical stress.
We suspect that they are left-over cells that failed to switch off
expression of -MHC in the manner that normally occurs
subsequent to birth.
In summary, we have generated a genetic model that allows a
precise and accurate assessment of the cellular distribution of
-MHC expression in normal or hypertrophic heart. Our anal-
yses reveal that reexpression of -MHC in hearts that are
hypertrophic is due to the occurrence of strong expression in a
subset of hypertrophic cardiac myocytes rather than to a general
increase of expression in all hypertrophic cells. We demonstrate
an essentially invariant association of -MHC reexpression in the
hypertrophic hearts with areas of perivascular and interstitial
fibrosis rather than with hypertrophy per se. This association also
is seen in the normal aging heart without the need for RenTg.
Thus, -MHC expression in the adult mouse heart is an indicator
of fibrosis rather than of hypertrophy.
Fig. 8. Increased numbers of -MHC-expressing cells are associated with
increased fibrosis during normal aging. Confocal images of ventricular sec-
tions from 9-month-old (A and B) and 26-month-old (C and D) Yb animals. (A
and C) YFP. (B and D) Fluorescent WGA lectin (pseudocolored blue). For each
animal, the same ventricular section was imaged for YFP and WGA lectin.
Percentages in the lower left corner of each image shows the fraction of tissue
positive for YFP expression (A and C) or WGA lectin staining (B and D). (Scale
bars: 500 m.)
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Materials and Methods
Generation of Mice with the YFP–-MHC Fusion Allele. Enhanced
YFP coding sequence with a valine–proline linker at the 3 end
was PCR-amplified and inserted at the start codon of a 2.7-kb
EcoRI -MHC fragment subcloned from a -phage library. The
resulting fragment was cloned into a targeting vector (41),
containing a 6.5-kb XhoBamHI 5 homology fragment (kind
gift from Jeffrey Robbins, University of Cincinnati, Cincinnati,
OH). Electroporation and selection of ES cells (E14) were
performed as described (42). Male chimeras generated from
targeted ES cells were bred to C57Bl6 females, and progeny
carrying the targeted allele were bred to RenTg mice (for details,
see Supporting Materials and Methods, which is published as
supporting information on the PNAS web site). Animals were
handled according to procedures approved by the Institutional
Animal Care and Use Committee.
RNA Analysis. RNA extraction and gene quantification were
carried out as described (43) by using published PCR primers
and probes (25) (for the sequences, see Supporting Materials and
Methods).
Tissue Processing. Hearts were procured as described (25) and
sectioned with a vibratome at 150-m thickness. Individual
sections were treated with sodium borohydride (1 mgml in PBS)
for 30 min at room temperature to reduce fixative-induced
fluorescence.
Confocal Analyses. Sections were stained with f luorescent
TRITC- or Alexa Fluor 633-labeled 50 gml WGA and ana-
lyzed with a FV500 confocal microscope (Olympus, Tokyo,
Japan) (see Supporting Materials and Methods for details on
lasers, image acquisition, and morphometric analyses). To quan-
tify the association between YFP expression and fibrosis, con-
focal sections from the left ventricle of a YbRentg animal were
digitally dissected into fibrotic and nonfibrotic areas (total
number of areas  44), and fibrosis (mean WGA pixel intensity)
and the YFP expression (mean YFP pixel intensity) of each area
were measured by using ImageJ.
Data Analysis. Values are reported as means  SEM. Bivariate
analyses were performed with JMP software (SAS institute,
Cary, NC). Unpaired two-tailed Student’s t test (Prism; Graph-
Pad, San Diego, CA) were used for comparisons between control
and RenTg groups, and differences were considered to be
statistically significant with P  0.05.
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